ArticleBMC microbiology2025
Six-year antimicrobial resistance patterns of Escherichia coli isolates from different hospitals in Gaza, Palestine.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Occurrence of Phenotypic Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Antibiofilm efficacy and genomic characterization of a lytic bacteriophage targeting MDR uropathogenic Escherichia coli.Archives of microbiology · 2026Article
- Green mycosynthesis of a CuO/ZnO heterojunction nanocomposite using Aspergillus terreus and its antibacterial and anti-virulence activity against multidrug-resistant Escherichia coli.Scientific reports · 2026Article
- A national surveillance study on five-year trends in AMR of E. coli from urine samples in Ethiopia.BMC infectious diseases · 2026Article
- Antimicrobial Resistance and Comparative Genome Analysis of High-RiskMicroorganisms · 2026Article
- Investigation of antibiotic resistance against pathogens isolated from respiratory samples in intensive care units after SARS-CoV-2 pandemic.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEscherichia coli is the foremost agent responsible for infections in humans, encompassing those affecting the urinary tract, ears, wounds, and various other regions. The escalating global issue of antimicrobial resistance in E. coli is raising significant apprehension. The aim of this study was to assess the frequency and susceptibility to antibiotics of E. coli based on gender, age, and the type of specimen.
methodsA retrospective review was conducted on culture outcomes from a total of 7,656 E. coli specimens primarily from urine, pus, sputum, vaginal swabs, and other specimens including cerebrospinal fluid (CSF), catheter tips, ear discharges and eye swabs, and ascitic fluid. Patients included 5,285 females (69%) and 2,371 males (31%), with age groups ranging from neonates (1 day to 29 days) to adults (> 12 years). The antimicrobial susceptibility was tested using the Kirby-Bauer disc diffusion method.
resultsE. coli strains displayed the highest levels of resistance to ampicillin and co-amoxiclav, with resistance rates reaching 90.3% and 78.7%, respectively. Conversely, these strains showed the lowest resistance to colistin (6.3%), followed by meropenem (9.9%) and amikacin (10.6%). Resistance patterns appeared to vary between males and females across most antibiotics, with similar trends observed across different age groups. Colistin resistance was notably higher among younger patients. Among the various specimen types analyzed, sputum samples generally exhibited the highest resistance rates for many antibiotics when compared to other specimen types.
conclusionThe resistance pattern of E. coli varies depending on gender, age, and specimen sources, and this should be taken into account when treating E. coli infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.